- Home
- TORO vs AKTX Comparison
TORO vs AKTX Comparison
Compare TORO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- AKTX
- Stock Information
- Founded
- TORO 2022
- AKTX N/A
- Country
- TORO Cyprus
- AKTX United States
- Employees
- TORO N/A
- AKTX N/A
- Industry
- TORO Marine Transportation
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- AKTX Health Care
- Exchange
- TORO Nasdaq
- AKTX Nasdaq
- Market Cap
- TORO 36.7M
- AKTX 35.7M
- IPO Year
- TORO N/A
- AKTX N/A
- Fundamental
- Price
- TORO $2.90
- AKTX $1.10
- Analyst Decision
- TORO
- AKTX
- Analyst Count
- TORO 0
- AKTX 0
- Target Price
- TORO N/A
- AKTX N/A
- AVG Volume (30 Days)
- TORO 755.9K
- AKTX 25.6K
- Earning Date
- TORO 08-11-2025
- AKTX 08-18-2025
- Dividend Yield
- TORO N/A
- AKTX N/A
- EPS Growth
- TORO N/A
- AKTX N/A
- EPS
- TORO 1.09
- AKTX N/A
- Revenue
- TORO $22,394,283.00
- AKTX N/A
- Revenue This Year
- TORO N/A
- AKTX N/A
- Revenue Next Year
- TORO N/A
- AKTX N/A
- P/E Ratio
- TORO $2.82
- AKTX N/A
- Revenue Growth
- TORO 0.40
- AKTX N/A
- 52 Week Low
- TORO $1.70
- AKTX $0.85
- 52 Week High
- TORO $4.05
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- TORO 70.90
- AKTX 39.44
- Support Level
- TORO $2.12
- AKTX $1.10
- Resistance Level
- TORO $3.37
- AKTX $1.15
- Average True Range (ATR)
- TORO 0.20
- AKTX 0.04
- MACD
- TORO 0.08
- AKTX 0.00
- Stochastic Oscillator
- TORO 66.90
- AKTX 0.00
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.